SleepNav CDSS – Accessibility Statement. Last updated: 18 March 2026.
This accessibility statement applies to the SleepNav Clinical Decision Support System at cdss.sleepnav.com.
This website is operated by Snorer.com Ltd. We want as many people as possible to be able to use this service. That means you should be able to change colours, contrast levels and fonts using browser or device settings, navigate most of the website using a keyboard, and use the website with a screen reader.
We are committed to making SleepNav accessible to all pharmacist users. The system is a web-based application accessed via standard browsers. Following a comprehensive WCAG 2.2 Level AA audit on 18 March 2026, all identified issues have been remediated.
The audit found that the site already had correct semantic landmarks, heading hierarchy, language attributes, and full keyboard navigation without traps. Remediation addressed colour contrast, focus indicators, form label associations, table header semantics, ARIA roles on modals, and a skip-to-content link. The site uses proper heading structure (h1 through h4), semantic HTML landmarks, and all clinical alert banners pass colour contrast requirements.
If you need information on this website in a different format, or if you experience any accessibility barriers, please contact us:
We are always looking to improve the accessibility of this website. If you find any problems not listed on this page or think we are not meeting accessibility requirements, please contact us at contact@sleepnav.com.
Snorer.com Ltd is committed to making this website accessible, in accordance with the Public Sector Bodies (Websites and Mobile Applications) (No. 2) Accessibility Regulations 2018.
This website is partially compliant with the Web Content Accessibility Guidelines (WCAG) 2.2 Level AA. A comprehensive audit was conducted on 18 March 2026. All issues identified during the audit have been remediated. No known non-compliances remain at the date of this statement. Automated accessibility scanning is not currently part of our build pipeline; adding it was a recommendation of the 18 March 2026 audit and remains outstanding. Until it is in place, accessibility is re-checked by manual review when pages change.
A WCAG 2.2 AA audit conducted on 18 March 2026 identified 29 issues (4 critical, 14 serious, 9 moderate, 2 minor). All issues were remediated on the same date. The following summarises the issues found and the actions taken.
No disproportionate burden claims are made. All identified issues have been remediated.
Patient-facing PDF reports generated by the system are not covered by these regulations. The PDF reports contain no patient-identifiable information and are intended to be printed and annotated by the pharmacist in consultation.
This statement was prepared on 18 March 2026 and was last reviewed on 18 March 2026. It was revised on 14 August 2026 to correct the description of the testing method below; no re-test was carried out on that date and no finding changed.
This website was last tested on 18 March 2026. Testing was carried out internally by manual expert analysis: review of the rendered HTML of 16 pages fetched with an authenticated session, static analysis of the page templates, CSS inspection and JavaScript review, together with keyboard navigation, colour contrast and screen reader landmark checks. Automated browser-based scanning (axe-core, pa11y) could not be run against the server, which lacks the shared libraries required for headless Chromium and where the deploying user has no permission to install them.
We tested the following pages and flows: